ACADIA PHARMACEUTICALS INC. Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31)
ACADIA PHARMACEUTICALS INC. (ACAD) reported Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) of 1.10% for the 1-month period ending 2012-12-31, per its 10-K filed 2016-02-29.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssumptionsRiskFreeInterestRate · last filed 2016-02-29
- 2012-12-31: Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 0 month 1.10%; Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 1 month 1.10%.
- 2011-01-31: Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 1 month 2.80%.
| Period end | Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 0 month | Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 1 month |
|---|---|---|
| 2012-12-31 | 1.10% 10-K · filed 2014-02-27 | 1.10% 10-K · filed 2016-02-29 |
| 2011-01-31 | 2.80% 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |